• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bull Horn Holdings Corp. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

    5/28/21 4:50:00 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BHSE alert in real time by email

    Bull Horn Holdings Corp. (NASDAQ:BHSE) (the "Company") today announced that it has received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the "Form 10-Q") in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq's continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1).

    As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission (the "SEC") on May 17, 2021, the Company was unable to file its Form 10-Q within the prescribed time period without unreasonable effort or expense due to the Company's conclusion (based on recently issued SEC guidance) that its outstanding public and private warrants should be accounted for as a liability and the resulting additional time required for updating the Company's financial statements accordingly. The extension period provided for filing the Form 10-Q under Rule 12b-25 expired on May 24, 2021.

    The Notice has no immediate effect on the listing or trading of the Company's securities.

    Nasdaq has informed the Company that, under Nasdaq rules, the Company will have 60 calendar days from the date of the Notice (May 28, 2021) to file its Form 10-Q with the SEC. The Company can regain compliance with Nasdaq listing standards during this sixty-day period when the Company files its Form 10-Q with the SEC. During the sixty-day period, Nasdaq will closely monitor the status of the Company's late filing and related public disclosures. If the Company fails to file its Form 10-Q within such sixty-day period, Nasdaq may, in its sole discretion, allow the Company's units, ordinary shares and warrants to trade for up to 180 days from the Form 10-Q's filing due date, or November 22, 2021 (an "Additional Period"), depending on specific circumstances, as outlined in the rule. If Nasdaq determines that an Additional Period is not appropriate, suspension and delisting procedures will commence pursuant to the Nasdaq Listing Rules. If Nasdaq determines that an Additional Period is appropriate and the Company fails to file its Form 10-Q and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence. Regardless of the procedures described above, Nasdaq may commence delisting proceedings at any time during the period that is available to complete the filing, if circumstances warrant.

    The Company is working diligently to complete its Form 10-Q. The Company intends to file the Form 10-Q as soon as practicable to regain compliance with the Nasdaq Listing Rules. No assurance can be given that the Company will be able to regain compliance with the Nasdaq timely filing listing requirement.

    About Bull Horn Holdings Corp.

    Bull Horn Holdings Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, the Company intends to focus on leading sports, entertainment and brand companies that have potential for brand and commercial growth. The Company is led by Chief Executive Officer, Robert Striar, and Chief Financial Officer, Christopher Calise. In addition to Messrs. Striar and Calise, the Board of Directors includes Stephen Master, Michael Gandler, Jeff Wattenberg, Doug Schaer and Baron Davis.

    Cautionary Note Regarding Forward-Looking Statements

    This press release may include, and oral statements made from time to time by representatives of the Company may include, "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company's management. Actual results (including the results of the Company's efforts to comply with Nasdaq listing standards as described herein) could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company's filings with the Securities and Exchange Commission ("SEC"). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus for the Company's initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210528005486/en/

    Get the next $BHSE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHSE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BHSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:03:11 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Cogley Brian claimed ownership of 30,000 shares (SEC Form 3)

    3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:01:21 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/16/24 8:14:38 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:03:11 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/16/24 8:14:38 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Yerace Daniel Alexander bought $7,486 worth of shares (10,850 units at $0.69), increasing direct ownership by 1% to 1,071,455 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/9/24 5:32:29 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    SEC Filings

    View All

    SEC Form 424B3 filed by Bull Horn Holdings Corp.

    424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/5/24 5:17:01 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Bull Horn Holdings Corp.

    424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/5/24 5:15:23 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bull Horn Holdings Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/1/24 5:28:10 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp.

    Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol "COEP" WEXFORD, Pa. and MIAMI, Oct. 31, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. ("Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings Corp. (NASDAQ:BHSE), a special purpose acquisition company ("Bull Horn").  In connection with the Business Combination, the combined company has been renamed "Coeptis Therapeutics Holdings, Inc." (the "Company") and its public shares and warrants are expected to commence trading on the Nasdaq G

    10/31/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology

    SNAP-CAR therapy provides a highly programmable therapeutic platform designed to potentially target many tumor types, including hematological malignancies and solid tumors WEXFORD, Pa., Sept. 21, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer.

    9/21/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors

    Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial

    5/17/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bull Horn Holdings Corp.

    SC 13G - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    2/14/24 3:32:56 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Bull Horn Holdings Corp. (Amendment)

    SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    2/6/23 4:25:12 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Bull Horn Holdings Corp.

    SC 13D - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    11/7/22 4:10:32 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care